VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.69 USD
+0.19 (7.40%)
Updated May 3, 2024 01:40 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYNE 2.69 +0.19(7.40%)
Will VYNE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2%
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
Other News for VYNE
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
12 Health Care Stocks Moving In Friday's After-Market Session
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
Vyne Therapeutics files for $250M mixed shelf